Anthonie van der Wekken

Search results

• 2024

  PS-20-007 PD-L1 expression in driver-mutated metastatic non-small cell lung cancer

  de Jager, V., Cajiao Garcia, B., Hempenius, M.-A., Kuijpers, C., van Kempen, L. C., Schuuring, E., van der Wekken, A. J. & Willems, S. M., 2024, In: Virchows Archiv. 485, Suppl 1, p. S139 1 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• PS-20-008 Predictive biomarker testing rates in patients with metastatic non-small cell lung cancer in The Netherlands

  de Jager, V., Cajiao Garcia, B., Kuijpers, C., de Bock, G. H., Maas, W., Timens, W., van Kempen, L. C., van der Wekken, A. J., Schuuring, E. & Willems, S. M., 2024, In: Virchows Archiv. 485, Suppl 1, p. S139-S140 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic
• 2023

  95P Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC)

  Cajiao Garcia, B., Koopman, B., de Jager, V., Oeste, C. L., Schuuring, E., van der Wekken, A. J., Willems, S. M. & van Kempen, L. C., Oct-2023, In: ESMO Open. 8, 1, Supplement 5, 1 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

  Open Access

  • Non Small Cell Lung Cancer 100%
  • Epidermal Growth Factor Receptor 100%
  • Data Processing 100%
  • Automatic Data Processing 100%
  • Prevalence 28%
• 2022

  A phase 1 study in patients with advanced non-small cell lung cancer treated with stereotactic radiotherapy to the primary tumor combined with durvalumab and tremelimumab

  Kievit, H., Muntinghe-Wagenaar, M. B., Ubbels, F., Wijsman, R., Hijmering-Kappelle, L., Hiddinga, B., Groen, H. J. M., Kerstjens, H. A. M., van der Wekken, A. J. & Hiltermann, T. J. N., 1-Jun-2022, In: Journal of Clinical Oncology. 40, 16_suppl, p. e21121-e21121 1 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• Predictive testing in stage-IV NSCLC within a network of collaborating hospitals

  Cajiao Garcia, B., van der Wekken, A., Willems, S., van Kempen, L. C. & Schuuring, E., Sept-2022, In: Virchows Archiv. 481, SUPPL 1, p. S306-S307 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic
• 2021

  Detection of on-target ALK inhibitor resistance mutations and treatment options for patients with non-small cell lung cancer

  UMCG Mol Tumor Board, Koopman, B., Groen, H. J. M., Schuuring, E., Timens, W., van Kempen, L. & Van der Wekken, A. J., Aug-2021, In: Virchows Archiv. 479, SUPPL 1, p. S59-S60 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from a phase II multicenter study, POSITION20

  Zwierenga, F., van Veggel, B. A. M. H., Hendriks, L. E. L., Hiltermann, T. J. N., Hiddinga, B. I., Hijmering-Kappelle, L. B. M., Dingemans, A.-M. C., van der Leest, C., de langen, A. J., van den Heuvel, M. & van der Wekken, A. J., 2021, In: Annals of Oncology. 32, S5, p. S966-S966 1 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study

  Gijtenbeek, R. G. P., Van Noort, V., Aerts, J. G. J. V., Staal-Van den Brekel, J. A., Smit, E. F., Krouwels, F. H., Wilschut, F. A., Hilterman, T. J. N., Timens, W., Schuuring, E., Janssen, J. D. J., Goosens, M., Van de Berg, P. M., De langen, A. J., Stigt, J. A., Van den Borne, B. E. E. M., Groen, H. J. M., Van Geffen, W. H. & Van der Wekken, A. J., 5-Sept-2021, In: European Respiratory Journal. 58, 3 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• Prevalence of KRAS p.(G12C) in stage IV non-squamous NSCLC patients in the Netherlands; a retrospective cohort study

  Garcia, B. C., Kuijpers, C. C., van der Wekken, A. J., van Kempen, L., Schuuring, E. & Willems, S., Aug-2021, In: Virchows Archiv. 479, Suppl. 1, p. S41 1 p.

  Research output: Contribution to journal › Meeting Abstract › Academic
• 2020

  Clinical value of EGFR gene amplifications detected using amplicon based targeted next generation sequencing data in lung adenocarcinoma patients

  Meng, P., Wei, J., Terpstra, M. M., van Rijk, A., Tamminga, M., Scherpen, F., ter Elst, A., Alimohamed, M. Z., Johansson, L. F., Hiltermann, T. J. N., Groen, H. J., Kok, K., van der Wekken, A. J. & van den Berg, A., Aug-2020, In: Cancer Research. 80, 16, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• Nationwide real-world cohort study of first line TKI treatment in epidermal growth factor receptor mutated non-small cell lung cancer

  Gijtenbeek, R. G. P., Damhuis, R. A. M., Groen, H. J. M., Van der Wekken, A. J. & Van Geffen, W. H., 7-Sept-2020, In: European Respiratory Journal. 56, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib

  Meng, P., Koopman, B., Kok, K., ter Elst, A., Schuuring, E., van Kempen, L. C., Timens, W., Hiltermann, T. J. N., Groen, H. J. M., van den Berg, A. & van der Wekken, A. J., Sept-2020, In: Annals of Oncology. 31, p. S1106-S1106 1 p.

  Research output: Contribution to journal › Meeting Abstract › Academic
• 2019

  An all-in-one transcriptome-based assay to identify therapy-related biomarkers in lung cancer

  Kok, K., Wei, J., Rybczynska, A. A., Meng, P., Terpstra, M. M., van der Wekken, A. J., Hiltermann, J. T., Schuuring, E., Groen, H. J. & van den Berg, A., Jul-2019, In: Cancer Research. 79, 13, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• ctDNA a promising predictive marker for treatment with PD-1 inhibitors in KRAS mutated NSCLC after platinum based chemotherapy

  Hiltermann, T. J. N., Hijmering-Kappelle, L. B. M., Azpurua, M. L. A., van der Wekken, A. J., Hiddinga, B. L., Timens, W., Groen, H. J. M. & Schuuring, E., Jul-2019, In: Cancer Research. 79, 13, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• Detecting therapy-guiding aberrations in platelets and plasma at the transcriptome level in non-small-cell lung cancer

  Meng, P., Rybczynska, A. A., Wei, J., Terpstra, M. M., Timens, W., Schuuring, E., Hiltermann, T. J. N., Groen, H. J. M., Kok, K., Van der Wekken, A. J. & Van den Berg, A., Nov-2019, In: Annals of Oncology. 30, 1 p., UNSP mdz413.025.

  Research output: Contribution to journal › Meeting Abstract › Academic

• Modeling of drug-protein interactions to support clinical decision making for therapy-resistant EGFR or ALK-positive non-small cell lung carcinoma

  Santos, J. F. V. M. R., Hiddinga, B. I., van Kempen, L. C., ter Elst, A., Hijmering, L. B., Hiltermann, T. J., Schuuring, E., Groves, M. R., Groen, H. J. & van der Wekken, A. J., Jul-2019, In: Cancer Research. 79, 13, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• PD-L1 expression, CD8 cells and MHC-class-1 Beta-2-microglobulin expression in advanced non-small lung cancer

  Hijmering-Kappelle, L., Hiltermann, J., Hiddinga, B., van der Wekken, A., 't Hart, N., Groen, H. & Timens, W., Jul-2019, In: Cancer Research. 79, 13, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic
• 2018

  Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer

  van Veggel, B., van der Wekken, A., Hashemi, S., Cornelissen, R., Monkhorst, K., Heideman, D., Radonic, T., Smit, E. F., Schuuring, E. & De Langen, J., Oct-2018, In: Annals of Oncology. 29, Suppl.8, p. viii524-viii525 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• Urine cell-free DNA as early biomarker in immunotherapy response in NSCLC

  van der Wekken, A. J., ter Elst, A., Miedema, A., Hiltermann, T. J., Goen, H. J. & Schuuring, E., Jul-2018, In: Cancer Research. 78, 13, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic
• 2017

  A comprehensive RNA-based assay for treatment prediction in non-small cell lung cancer patients

  Kok, K., Wei, J., Rybczynska, A., Terpstra, M., van der Wekken, A., Hilterman, J., Schuuring, E., Sijmons, R., Groen, H. & van den Berg, A., Jul-2017, In: Cancer Research. 77, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• All-in-one RNA-based assay to detect therapeutic biomarkers in lung cancer

  Wei, J., Rybczynska, A., van der Wekken, A., Saber, A., Terpstra, M., Schuuring, E., Timens, W., Hiltermann, T., Groen, H., van den Berg, A. & Kok, K., Oct-2017, In: Annals of Oncology. 28, 1 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• First-in-human PET imaging with the PD-L1 antibody Zr-89-atezolizumab

  Bensch, F., van der Veen, E., Jorritsma, A., Lub-de Hooge, M., Boellaard, R., Oosting, S., Schröder, C., Hiltermann, J., van der Wekken, A., Groen, H., Fine, B., McKnight, N., Bohorquez, S. S., Williams, S., Veronese, L., Mancao, C., Brouwers, A. H. & de Vries, E., Jul-2017, In: Cancer Research. 77, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• Molecular Tumor Board treatment predictions on rare EGFR exon 20 mutations

  van der Wekken, A. J., Groves, M. R., ter Elst, A., 't Hart, N. A., Hijmering-Kappelle, L. B., Hiltermann, T. J., van den Berg, A., Timens, W., Schuuring, E. & Groen, H. J., Jul-2017, In: Cancer Research. 77, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• Treatment decision-making of rare ERBB2 (HER2) mutations in lung cancer; a role for multidisciplinary molecular tumor boards: A role for multidisciplinary molecular tumor boards

  ter Elst, A., 't Hart, N. A., van der Wekken, A. J., Timens, W., Hijmering-Kappelle, L. B., Hospers, G. A., Jalving, H., van der Logt, E. M., van Kempen, L. C., Oosting, S. F., Groves, M. R., Hiltermann, T. J., van den Berg, A., Groen, H. J. & Schuuring, E., Jul-2017, In: Cancer Research. 77, 2 p., Abstract 754.

  Research output: Contribution to journal › Meeting Abstract › Academic
• 2016

  The efficacy and safety of CT-guided percutaneous hookwire localization in VATS for pulmonary nodules

  Klinkenberg, T., Dinjens, L., Rienhart, W., van der Wekken, A. J., Groen, H. J. M., Timens, W., Van De Wauwer, C., de Bock, G. H., Mariani, M. & van Geffen, W., 1-Sept-2016, In: European Respiratory Journal. 48, 1 p.

  Research output: Contribution to journal › Meeting Abstract › Academic
• 2015

  Comparison of Different ALK Tests in Non-Small Cell Lung Cancer (NSCLC) Patients before and after Crizotinib and Their Clinical Outcome

  van der Wekken, A. J., Hart, N. T., Hiltermann, T., Timens, W., Groen, H. J. & Schuuring, E., Sept-2015, In: Journal of Thoracic Oncology. 10, 9, p. S378-S378 1 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• Comparison of different ALK tests in non-small cell lung cancer (NSCLC) patients treated with crizotinib and their clinical outcome

  Wekken, van der, A. J., Hiltermann, T. J. N., Timens, W., Schuuring, E. & Groen, H. J. M., 1-Aug-2015, In: Cancer Research. 75, 3 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• Detection of fusion genes in lung cancer biopsies of crizotinib resistant patients

  Saber, A., van der Wekken, A., Kok, K., Terpstra, M. M., Mastik, M. F., Timens, W., Schuuring, E. M. D., Hiltermann, T. J., Groen, H. J. M. & van den Berg, A., 1-Aug-2015, In: Cancer Research. 75, 3 p.

  Research output: Contribution to journal › Meeting Abstract › Academic
• 2013

  Pre-treatment EGFR mutation analysis predicts clinical outcome in a retrospective analysis of 24 non-squamous non-small-cell lung cancer (NSCLC) patients treated with second line afatinib.

  Wekken, van der, A. J., Kuiper, J. L., Heideman, D. A. M., Schuuring, E., Timens, W., Thunnissen, E., Groen, H. J. M. & Smit, E. F., 15-Apr-2013, In: Cancer Research. 73, 8, p. 3526

  Research output: Contribution to journal › Meeting Abstract › Academic